Incannex Healthcare Limited IXHL · Stock Open Incannex Healthcare Limited in new tab
Analyst price targets
Recent rating changes, newest first
Incannex Healthcare Limited Analysis (IXHL)
Is Incannex Healthcare Limited a good investment? Incannex Healthcare Limited (IXHL) is currently trading at 3.10 USD. Market analysts have a consensus price target of 18.69 USD. This suggests a potential upside from current levels.
Earnings Schedule: Incannex Healthcare Limited is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -1.71.
Investor FAQ
Does Incannex Healthcare Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Incannex Healthcare Limited?
Incannex Healthcare Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -1.66.
Company Profile
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 27, 2026 | 1:30 |
Community Discussion